Microbiome-Based Therapies in Parkinson's Disease : Can Tuning the Microbiota Become a Viable Therapeutic Strategy?
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Progressive neurodegenerative disorders such as Parkinson's disease (PD) have continued to baffle medical science, despite strides in the understanding of their pathology. The inability of currently available therapies to halt disease progression is a testament to an incomplete understanding of pathways crucial to disease initiation, progression and management. Science has continued to link the activities and equilibrium of the gut microbiome to the health and proper functioning of brain neurons. They also continue to stir interest in the potential applications of technologies that may shift the balance of the gut microbiome towards achieving a favourable outcome in PD management. There have been suggestions that an improved understanding of the roles of the gut microbiota is likely to lead to the emergence of an era where their manipulation becomes a recognized strategy for PD management. This review examines the current state of our journey in the quest to understand how the gut microbiota can influence several aspects of PD. We highlight the relationship between the gut microbiome/microbiota and PD pathogenesis, as well as preclinical and clinical evidence evaluating the effect of postbiotics, probiotics and prebiotics in PD management. This is with a view to ascertaining if we are at the threshold of discovering the application of a usable tool in our quest for disease modifying therapies in PD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
CNS & neurological disorders drug targets - (2022) vom: 03. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Onaolapo, Adejoke Y [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alpha-synuclein |
|---|
| Anmerkungen: |
Date Revised 16.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/1871527321666220903114559 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345740505 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345740505 | ||
| 003 | DE-627 | ||
| 005 | 20240217232038.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871527321666220903114559 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1297.xml |
| 035 | |a (DE-627)NLM345740505 | ||
| 035 | |a (NLM)36056826 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Onaolapo, Adejoke Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Microbiome-Based Therapies in Parkinson's Disease |b Can Tuning the Microbiota Become a Viable Therapeutic Strategy? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Progressive neurodegenerative disorders such as Parkinson's disease (PD) have continued to baffle medical science, despite strides in the understanding of their pathology. The inability of currently available therapies to halt disease progression is a testament to an incomplete understanding of pathways crucial to disease initiation, progression and management. Science has continued to link the activities and equilibrium of the gut microbiome to the health and proper functioning of brain neurons. They also continue to stir interest in the potential applications of technologies that may shift the balance of the gut microbiome towards achieving a favourable outcome in PD management. There have been suggestions that an improved understanding of the roles of the gut microbiota is likely to lead to the emergence of an era where their manipulation becomes a recognized strategy for PD management. This review examines the current state of our journey in the quest to understand how the gut microbiota can influence several aspects of PD. We highlight the relationship between the gut microbiome/microbiota and PD pathogenesis, as well as preclinical and clinical evidence evaluating the effect of postbiotics, probiotics and prebiotics in PD management. This is with a view to ascertaining if we are at the threshold of discovering the application of a usable tool in our quest for disease modifying therapies in PD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alpha-synuclein | |
| 650 | 4 | |a dietary fibre | |
| 650 | 4 | |a gut-brain axis | |
| 650 | 4 | |a postbiotics | |
| 650 | 4 | |a prebiotics | |
| 650 | 4 | |a synbiotics. | |
| 700 | 1 | |a Ojo, Folusho O |e verfasserin |4 aut | |
| 700 | 1 | |a Olofinnade, Anthony T |e verfasserin |4 aut | |
| 700 | 1 | |a Falade, Joshua |e verfasserin |4 aut | |
| 700 | 1 | |a Lawal, Ismail A |e verfasserin |4 aut | |
| 700 | 1 | |a Onaolapo, Olakunle J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS & neurological disorders drug targets |d 2006 |g (2022) vom: 03. Sept. |w (DE-627)NLM161975518 |x 1996-3181 |7 nnns |
| 773 | 1 | 8 | |g year:2022 |g day:03 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871527321666220903114559 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 03 |c 09 | ||